psychotropic treatment
Recently Published Documents


TOTAL DOCUMENTS

35
(FIVE YEARS 4)

H-INDEX

9
(FIVE YEARS 1)

2020 ◽  
pp. 1-9 ◽  
Author(s):  
Hélène Verdoux ◽  
Clélia Quiles ◽  
Laura Bon ◽  
Isabelle Chéreau-Boudet ◽  
Julien Dubreucq ◽  
...  

Abstract Background Few studies have explored whether high-anticholinergic load may hamper rehabilitation in persons with schizophrenia. We aim to explore the associations between anticholinergic load of psychotropic treatment and functioning or cognitive performances of persons with psychosis engaged in psychosocial rehabilitation. Methods The study was performed using data collected at baseline assessment in the REHABase cohort including persons referred to a French network of psychosocial rehabilitation centers. The composite-rating scale developed by Salahudeen et al. was used to rate the anticholinergic load of psychotropic drugs prescribed at baseline assessment. The associations between total anticholinergic load score (categorized as ‘low’ <3 v. ‘high’ ⩾3) and functioning or cognitive characteristics were explored using multivariate analyses. Results Of the 1012 participants with schizophrenia spectrum disorders identified in the REHABase, half used at least two psychotropic drugs with anticholinergic activity and one out of three was prescribed at least one psychotropic drug with high-anticholinergic activity. High-anticholinergic load was significantly associated with lower stage of recovery [odds ratio (OR) = 1.70, 95% confidence interval (CI) 1.05–2.76, p = 0.03], poor mental well-being (OR = 1.55, 95% CI 1.02–2.33, p = 0.04) and poor self-rated medication adherence (OR = 2.14, 95% CI 1.29–3.53, p = 0.003). Regarding cognition, a high-anticholinergic score was associated with poorer delayed-episodic memory (OR = 1.69, 95% CI 1.01–2.85, p = 0.05) and at the trend level with faster completion time on the test exploring executive performance (OR = 0.67, 95% CI 0.43–1.04, p = 0.07). Conclusions The psychosocial rehabilitation plan of persons with psychosis should integrate optimization of psychotropic treatment in order to lessen the functional and cognitive impact of high-anticholinergic load.


2016 ◽  
Vol 26 (12) ◽  
pp. 547-557 ◽  
Author(s):  
Frederik Vandenberghe ◽  
Núria Saigí-Morgui ◽  
Aurélie Delacrétaz ◽  
Lina Quteineh ◽  
Séverine Crettol ◽  
...  

2016 ◽  
Vol 27 (7) ◽  
pp. 582-598
Author(s):  
Darren R. Bernal ◽  
Rachel Becker Herbst ◽  
Brian L. Lewis ◽  
Jennifer Feibelman

2016 ◽  
Vol 46 (8) ◽  
pp. 428-428
Author(s):  
Jan Fawcett

2015 ◽  
Vol 23 (2) ◽  
pp. 140-148 ◽  
Author(s):  
Xinyue Liu ◽  
Vaishali Shah ◽  
Paul Kubilis ◽  
Dandan Xu ◽  
Regina Bussing ◽  
...  

Objective: To describe psychotropic treatment pattern and evaluate the association of socio-demographic factors and psychotropic combination therapy in children with ADHD and oppositional defiant disorder/conduct disorder (ODD/CD). Method: This is a cross-sectional drug utilization study based on Medicaid fee-for-service programs in 26 U.S. states (1999-2006). Children aged 4 to 18 with concomitant ADHD and ODD/CD were included. We calculated the prevalence of psychotropic drugs and used logistic regression to evaluate the role of socio-demographic factors in psychotropic combination therapy. Results: We identified 121,740 children with ADHD and ODD/CD (140,777 person-years). The period prevalence of “no psychotropic therapy,” psychotropic monotherapy, and psychotropic dual therapy was 38.1%, 44.7%, and 9.0%, respectively. The most common drug class was stimulants. Whites, males, and children in foster care were more likely to use psychotropic combination therapy. State-level variation was observed. Conclusion: “No psychotropic therapy” and stimulants dominate treatment choices in children with ADHD and ODD/CD. Socio-demographic characteristics are associated with combination psychotropic therapy.


Sign in / Sign up

Export Citation Format

Share Document